Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab191893-100μg
|
100μg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$59.90
|
|
|
Ab191893-1mg
|
1mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$289.90
|
|
|
Ab191893-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$639.90
|
|
|
Ab191893-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,029.90
|
|
Purity≥95% (SDS-PAGE&SEC-HPLC); Endotoxin Level<1.0 EU/mg; Human IgG1; CHO; ELISA, Flow Cytometry, Functional assay, Animal Model; Unconjugated
| Product Name | Ifabotuzumab (anti-EphA3) - Primary antibody, specific to EPHA3, Human IgG1 |
|---|---|
| Synonyms | AW492086 antibody | Cek4 antibody | EC 2.7.10.1 antibody | EK4 antibody | End3 antibody | Eph receptor A3 antibody | EPH-like kinase 4 antibody | EPH-like tyrosine kinase 1 antibody | EPHA3 antibody | EPHA3_HUMAN antibody | Ephrin receptor EphA3 antibody |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Biochemical and Physiological Mechanisms | Receptor for members of the ephrin-A family. Binds to ephrin-A2, -A3, -A4 and -A5. Could play a role in lymphoid function. |
| Host species | Human |
| Specificity | EPHA3 |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Product Description |
Ifabotuzumab (anti-EphA3) is an IgG1κ antibody targeting EphA3 (KD=610 pM). Ifabotuzumab (anti-EphA3) induces tumor cell apoptosis, activates Antibody-dependent cell mediated cytotoxicity (ADCC), and damages tumor vasculature. Ifabotuzumab (anti-EphA3) reduces human idiopathic pulmonary fibrosis (IPF) CCR10+ cells and improves pulmonary fibrosis. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 145.4 kDa |
| Purification Method | Protein A purified |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| CAS | 2147698-66-4 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Ifabotuzumab (anti-EphA3) (Ab191893) - ELISA
Immobilized Recombinant Human EphA3 his protein at 2.0 μg/mL can bind Ifabotuzumab (anti-EphA3) (Ab191893) with the EC₅₀ of 2.95 ng/mL.
Ifabotuzumab (anti-EphA3) (Ab191893) - SEC
The purity of Ifabotuzumab (anti-EphA3) (Ab191893) is more than 95% verified by HPLC.